Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Aleniglipron (Structure Therapeutics) -- Phase 2# Aleniglipron has produced the most competitive oral weight loss data to date: ACCESS: 11.3% placebo-adjusted weight loss at 36 weeks (120 mg) ACCESS II: 15.3% placebo-adjusted weight loss at 36 weeks (240 mg) Low-dose initiation (2.5 mg) significantly improved tolerability Phase 3 planned for mid-2026 At 36 weeks, aleniglipron's trajectory suggests it could approach injectable-level efficacy with longer treatment duration
Professional consultation healthcare
Ascend Peptides UK provides fully compliant, research-only labelled products and makes no health, clinical, metabolic, or performance-related claims about any compound in our range
Every opening creates a temperature swing of several degrees
Throughout your weight loss journey, our medical team closely monitors your progress, making adjustments as necessary to maintain optimal health and safety
